JP2011513204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513204A5 JP2011513204A5 JP2010536259A JP2010536259A JP2011513204A5 JP 2011513204 A5 JP2011513204 A5 JP 2011513204A5 JP 2010536259 A JP2010536259 A JP 2010536259A JP 2010536259 A JP2010536259 A JP 2010536259A JP 2011513204 A5 JP2011513204 A5 JP 2011513204A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation according
- polymer
- active ingredient
- pharmaceutically active
- fine granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims description 77
- 239000008187 granular material Substances 0.000 claims description 76
- 238000002360 preparation method Methods 0.000 claims description 72
- 239000004480 active ingredient Substances 0.000 claims description 53
- 238000000576 coating method Methods 0.000 claims description 50
- 239000011248 coating agent Substances 0.000 claims description 49
- 229920001577 copolymer Polymers 0.000 claims description 48
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 38
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 36
- 239000011247 coating layer Substances 0.000 claims description 36
- 238000013270 controlled release Methods 0.000 claims description 36
- 239000007771 core particle Substances 0.000 claims description 26
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 24
- 239000010410 layer Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 239000010419 fine particle Substances 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 21
- -1 phthalate ester Chemical class 0.000 claims description 20
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 19
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 19
- 239000002245 particle Substances 0.000 claims description 17
- 239000004014 plasticizer Substances 0.000 claims description 16
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 13
- 239000001856 Ethyl cellulose Substances 0.000 claims description 12
- 238000005266 casting Methods 0.000 claims description 12
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 12
- 229920001249 ethyl cellulose Polymers 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 12
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 11
- 229920001800 Shellac Polymers 0.000 claims description 11
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 229960003943 hypromellose Drugs 0.000 claims description 11
- 239000004208 shellac Substances 0.000 claims description 11
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 11
- 229940113147 shellac Drugs 0.000 claims description 11
- 235000013874 shellac Nutrition 0.000 claims description 11
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical group CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 10
- 239000001069 triethyl citrate Substances 0.000 claims description 10
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 10
- 235000013769 triethyl citrate Nutrition 0.000 claims description 10
- 230000001419 dependent effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 3
- 239000000612 proton pump inhibitor Substances 0.000 claims description 3
- MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 claims description 2
- 229960003568 dexlansoprazole Drugs 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 2
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 2
- 229960003174 lansoprazole Drugs 0.000 claims description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 description 19
- 239000001913 cellulose Substances 0.000 description 19
- 235000010980 cellulose Nutrition 0.000 description 19
- 239000002702 enteric coating Substances 0.000 description 17
- 238000009505 enteric coating Methods 0.000 description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 16
- 239000008101 lactose Substances 0.000 description 16
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 8
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 6
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 4
- 239000012792 core layer Substances 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 239000004503 fine granule Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000001087 glyceryl triacetate Substances 0.000 description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229960002622 triacetin Drugs 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920003139 Eudragit® L 100 Polymers 0.000 description 2
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 2
- 229920003141 Eudragit® S 100 Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000593312 Selfia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- CYPSCVSJKNUDRN-UHFFFAOYSA-N C(C=C)(=O)OC.CC(C(=O)O)=C.C(C(=C)C)(=O)O Chemical compound C(C=C)(=O)OC.CC(C(=O)O)=C.C(C(=C)C)(=O)O CYPSCVSJKNUDRN-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003159 Eudragit® RS 100 Polymers 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical class [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 description 1
- JCPWEYMVKJCSHJ-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O.COC(=O)C(C)=C JCPWEYMVKJCSHJ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010536259A JP5604304B2 (ja) | 2008-03-11 | 2009-03-10 | 口腔内崩壊性固形製剤 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008061673 | 2008-03-11 | ||
| JP2008061673 | 2008-03-11 | ||
| JP2008334920 | 2008-12-26 | ||
| JP2008334920 | 2008-12-26 | ||
| PCT/JP2009/054983 WO2009113703A2 (en) | 2008-03-11 | 2009-03-10 | Orally-disintegrating solid preparation |
| JP2010536259A JP5604304B2 (ja) | 2008-03-11 | 2009-03-10 | 口腔内崩壊性固形製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011513204A JP2011513204A (ja) | 2011-04-28 |
| JP2011513204A5 true JP2011513204A5 (enExample) | 2012-04-26 |
| JP5604304B2 JP5604304B2 (ja) | 2014-10-08 |
Family
ID=40791576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010536259A Expired - Fee Related JP5604304B2 (ja) | 2008-03-11 | 2009-03-10 | 口腔内崩壊性固形製剤 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9241910B2 (enExample) |
| EP (1) | EP2254556A2 (enExample) |
| JP (1) | JP5604304B2 (enExample) |
| KR (1) | KR20100129761A (enExample) |
| CN (2) | CN104127368A (enExample) |
| AR (1) | AR070863A1 (enExample) |
| AU (1) | AU2009224254A1 (enExample) |
| BR (1) | BRPI0909439A2 (enExample) |
| CA (1) | CA2717947C (enExample) |
| CL (1) | CL2009000557A1 (enExample) |
| CO (1) | CO6321224A2 (enExample) |
| CR (1) | CR11709A (enExample) |
| DO (1) | DOP2010000273A (enExample) |
| EA (1) | EA021792B1 (enExample) |
| EC (1) | ECSP10010538A (enExample) |
| GE (1) | GEP20135845B (enExample) |
| IL (1) | IL207989A0 (enExample) |
| MA (1) | MA32174B1 (enExample) |
| MX (1) | MX2010009824A (enExample) |
| MY (1) | MY173730A (enExample) |
| NZ (1) | NZ588407A (enExample) |
| PE (2) | PE20091620A1 (enExample) |
| TW (1) | TWI441658B (enExample) |
| UY (1) | UY31698A (enExample) |
| WO (1) | WO2009113703A2 (enExample) |
| ZA (1) | ZA201006679B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY173730A (en) | 2008-03-11 | 2020-02-18 | Takeda Pharmaceuticals Co | Orally-disintegrating solid preparation |
| CA2729015A1 (en) * | 2008-06-26 | 2009-12-30 | Mcneil-Ppc, Inc. | Coated particles containing pharmaceutically active agents |
| JP5753661B2 (ja) | 2009-01-26 | 2015-07-22 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロース水分散液を用いた湿式造粒打錠法 |
| EP2319504A1 (en) * | 2009-11-07 | 2011-05-11 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical solid dosage form |
| US20130216617A1 (en) * | 2010-06-29 | 2013-08-22 | Cadila Healthcare Limited | Pharmaceutical compositions of (r)-lansoprazole |
| JP2014501224A (ja) * | 2010-12-27 | 2014-01-20 | 武田薬品工業株式会社 | 口腔内崩壊錠 |
| CN102716097A (zh) * | 2012-05-29 | 2012-10-10 | 浙江华海药业股份有限公司 | 控制口腔崩解片药物释放速率的方法 |
| FI126168B (en) | 2012-09-18 | 2016-07-29 | Novaldmedical Ltd Oy | A method for coating pharmaceutical substrates |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| AU2015290098B2 (en) | 2014-07-17 | 2018-11-01 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
| EP3257511B1 (en) * | 2015-02-10 | 2018-10-24 | FUJIFILM Corporation | Orally disintegrating tablet and method for manufacturing same |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US20190054029A1 (en) * | 2016-02-23 | 2019-02-21 | Nipro Corporation | Pharmaceutical composition particles, orally disintegrating preparation including same, and method for producing pharmaceutical composition particles |
| US10751408B2 (en) | 2016-02-23 | 2020-08-25 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens |
| GB201607548D0 (en) * | 2016-04-29 | 2016-06-15 | Univ Central Lancashire | Solid dosage form |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| JOP20190008A1 (ar) | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
| EP3563847B1 (en) * | 2016-12-28 | 2023-09-20 | FUJIFILM Toyama Chemical Co., Ltd. | Pharmaceutical composition |
| WO2018155435A1 (ja) * | 2017-02-21 | 2018-08-30 | Ｅａファーマ株式会社 | 顆粒製剤 |
| JP7235193B2 (ja) * | 2017-04-26 | 2023-03-08 | 大正製薬株式会社 | 固形組成物 |
| JP7009288B2 (ja) * | 2017-05-18 | 2022-01-25 | エルメッド株式会社 | 湿製錠剤の製造方法及び湿製錠剤の品質向上方法 |
| JP7336187B2 (ja) * | 2017-11-30 | 2023-08-31 | 日本ケミファ株式会社 | 多層構造を有する粒子状医薬組成物 |
| WO2019143744A1 (en) | 2018-01-16 | 2019-07-25 | Applied Materials, Inc. | Metal oxide encapsulated drug compositions and methods of preparing the same |
| CN111601591A (zh) | 2018-01-24 | 2020-08-28 | 普渡制药公司 | 睡眠障碍的治疗和预防 |
| TW201940171A (zh) * | 2018-02-08 | 2019-10-16 | 景凱生物科技股份有限公司 | 類鴉片受體拮抗劑之固體劑型用之醫藥劑型 |
| US12371427B2 (en) | 2019-01-31 | 2025-07-29 | Purdue Pharma L.P. | Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound |
| US12233169B2 (en) | 2019-08-27 | 2025-02-25 | Applied Materials, Inc. | Vapor phase coating technology for pharmaceutical abuse deterrent formulations |
| JP2022545279A (ja) | 2019-08-27 | 2022-10-26 | アプライド マテリアルズ インコーポレイテッド | 医薬品の溶解度制御のための気相コーティング |
| GB202001237D0 (en) * | 2020-01-29 | 2020-03-11 | Sisteks D O O | Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product |
| EP4096791A1 (en) | 2020-01-31 | 2022-12-07 | Nanocopoeia LLC | Amorphous nilotinib microparticles and uses thereof |
| IL297776A (en) | 2020-04-30 | 2022-12-01 | Nanocopoeia Llc | Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib |
| TWI870622B (zh) | 2020-10-02 | 2025-01-21 | 美商應用材料股份有限公司 | 製備氧化矽塗佈藥品的低溫處理 |
| CN112121067A (zh) * | 2020-11-16 | 2020-12-25 | 深圳科兴药业有限公司 | 一种婴儿型双歧杆菌微胶囊及其制备方法 |
| JP2023553010A (ja) | 2020-12-03 | 2023-12-20 | バテル・メモリアル・インスティテュート | 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法 |
| EP4320233A4 (en) | 2021-04-07 | 2025-08-13 | Battelle Memorial Institute | RAPID DESIGN, BUILD, TEST, AND LEARNING TECHNOLOGIES TO IDENTIFY AND USE NON-VIRAL VECTORS |
| BR112023023702A2 (pt) | 2021-05-21 | 2024-01-30 | Purdue Pharma Lp | Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga |
| US12491165B2 (en) | 2021-09-30 | 2025-12-09 | Applied Materials, Inc. | Low temperature silicon oxide coating for pharmaceutical applications |
| US20250195417A1 (en) * | 2022-03-22 | 2025-06-19 | Daicel Corporation | Additive composition for orally disintegrating tablet |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| AU2024364388A1 (en) | 2023-10-19 | 2026-03-19 | Purdue Pharma L.P. | Sunobinop for use in method of treating alcohol use disorder |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
| CN117860699A (zh) * | 2024-01-07 | 2024-04-12 | 长沙晶易医药科技股份有限公司 | 一种细粒剂及其制备方法 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62277322A (ja) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
| CA1327010C (en) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
| FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
| US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
| SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| EP2263660B1 (en) | 1998-05-18 | 2017-09-27 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets |
| DE69942777D1 (de) | 1998-07-28 | 2010-10-28 | Takeda Pharmaceutical | Leicht zerfallende feste Zubereitung |
| EP2266542A3 (en) | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| TWI275587B (en) | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
| HU229291B1 (en) * | 2001-01-31 | 2013-10-28 | Evonik Roehm Gmbh | Multi-particulate form of medicament, comprising at least two differently coated forms of pellet |
| HUP0401941A3 (en) | 2001-07-16 | 2008-04-28 | Astrazeneca Ab | Pharmaceutical formulation comprising a proton pomp inhibitor and antacids and process for its preparation |
| DE10208335A1 (de) | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Arzneiform und Verfahren zu ihrer Herstellung |
| AUPS167602A0 (en) | 2002-04-12 | 2002-05-16 | F.H. Faulding & Co. Limited | An improved modified release preparation |
| MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| US20040096497A1 (en) | 2002-11-19 | 2004-05-20 | Ponder Garratt W. | Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions |
| MXPA04010956A (es) | 2003-01-30 | 2005-01-25 | Roehm Gmbh | Forma de dosis farmaceutica y metodo para la produccion de la misma. |
| WO2005009410A2 (en) | 2003-07-17 | 2005-02-03 | Dr. Reddy's Laboratories, Inc. | Pharmaceutical compositions having a swellable coating |
| AU2004275835B2 (en) | 2003-09-26 | 2011-06-23 | Alza Corporation | Controlled release formulations exhibiting an ascending rate of release |
| GB0323232D0 (en) * | 2003-10-03 | 2003-11-05 | Rolls Royce Plc | Electrical machine |
| EP1750717B1 (en) | 2004-02-11 | 2017-07-19 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| US20050181052A1 (en) | 2004-02-17 | 2005-08-18 | Patel Satishkumar A. | Lansoprazole microtablets |
| US20050214371A1 (en) | 2004-03-03 | 2005-09-29 | Simona Di Capua | Stable pharmaceutical composition comprising an acid labile drug |
| EP1721604A4 (en) | 2004-03-04 | 2008-04-30 | Takeda Pharmaceutical | STABLE CAPSULE PREPARATION |
| US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
| EP1787640A4 (en) * | 2004-04-30 | 2012-04-11 | Astellas Pharma Inc | GRAINED PHARMACEUTICAL COMPOSITION WITH TEMPORARY DELIVERY FOR ORAL ADMINISTRATION AND FAST-DECREASING INTRAORAL TABLET WITH THE COMPOSITION |
| DE102004035936A1 (de) | 2004-07-23 | 2006-03-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform |
| WO2006101536A1 (en) * | 2004-11-04 | 2006-09-28 | Akina, Inc. | Fast-melting tablets having taste-masking and sustained release properties |
| WO2006070845A1 (ja) | 2004-12-28 | 2006-07-06 | Eisai R & D Management Co., Ltd. | 速崩壊性錠剤及びその製造方法 |
| GB0502479D0 (en) | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
| FR2885526B1 (fr) | 2005-05-13 | 2007-07-27 | Flamel Technologies Sa | Medicament oral a base d'inhibiteur de pompe a protons |
| DE102005024614A1 (de) | 2005-05-25 | 2006-11-30 | Röhm Gmbh | Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug |
| CA2614526A1 (en) | 2005-07-11 | 2006-10-12 | Nycomed Danmark Aps | Benzimidazole formulation |
| DE102005032806A1 (de) | 2005-07-12 | 2007-01-18 | Röhm Gmbh | Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten |
| WO2007037259A1 (ja) | 2005-09-29 | 2007-04-05 | Eisai R & D Management Co., Ltd. | 生体内での崩壊性を向上させたパルス製剤 |
| FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| EP1813275A1 (en) * | 2005-12-20 | 2007-08-01 | Teva Pharmaceutical Industries Ltd | Lansoprazole orally disintegrating tablets |
| CA2633825A1 (en) | 2005-12-20 | 2007-07-05 | Teva Pharmaceutical Industries Ltd. | Lansoprazole orally disintegrating tablets |
| JP2009519334A (ja) | 2005-12-20 | 2009-05-14 | テバ ファーマシューティカル インダストリーズ リミティド | ランソプラゾール経口崩壊錠剤 |
| US20070141151A1 (en) | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
| JP5053865B2 (ja) | 2005-12-28 | 2012-10-24 | 武田薬品工業株式会社 | 口腔内崩壊性固形製剤の製造法 |
| KR100762847B1 (ko) | 2006-01-27 | 2007-10-04 | 씨제이 주식회사 | 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법 |
| EP1837016A3 (en) | 2006-03-08 | 2008-01-02 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical multiple-unit composition |
| US20090068263A1 (en) | 2006-04-20 | 2009-03-12 | Themis Laboratories Private Limited | Multiple unit compositions |
| JP5826456B2 (ja) | 2006-04-26 | 2015-12-02 | アルファファーム ピーティーワイ リミテッド | コーティングされていない分離したユニットおよび延長放出マトリクスを含む制御放出配合物 |
| ES2466441T3 (es) | 2006-04-28 | 2014-06-10 | Wockhardt Limited | Composiciones farmacéuticas que comprenden fármaco antiinflamatorio no esteroideo, acetaminofén e inhibidor de la bomba de protones |
| US20070292510A1 (en) | 2006-06-19 | 2007-12-20 | Hugh Huang | Enteric coated particles containing an active ingredient |
| US20090291136A1 (en) | 2006-07-11 | 2009-11-26 | Lek Pharmaceuticals D.D. | Multiple Unit Tablets |
| WO2008014175A2 (en) | 2006-07-28 | 2008-01-31 | Dr. Reddy's Laboratories Ltd. | Granular pharmaceutical compositions |
| WO2008025535A1 (en) | 2006-08-30 | 2008-03-06 | Jagotec Ag | Controlled release oral dosage formulations comprising a core and one or more barrier layers |
| WO2008081891A1 (ja) * | 2006-12-28 | 2008-07-10 | Takeda Pharmaceutical Company Limited | 口腔内崩壊性固形製剤 |
| DE102007009243A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| DE102007009242A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit magensaftresistenter Wirkstoff-Matix |
| PT2152250T (pt) | 2007-05-07 | 2019-12-12 | Evonik Operations Gmbh | Formas farmacêuticas sólidas que compreendem um revestimento entérico com libertação acelerada do fármaco |
| MY173730A (en) | 2008-03-11 | 2020-02-18 | Takeda Pharmaceuticals Co | Orally-disintegrating solid preparation |
| WO2010008569A1 (en) | 2008-07-17 | 2010-01-21 | Barr Laboratories, Inc. | Orally disintegrating solid pharmaceutical dosage forms comprising delayed-release lansoprazole and methods of making and using the same |
| JP2014501224A (ja) | 2010-12-27 | 2014-01-20 | 武田薬品工業株式会社 | 口腔内崩壊錠 |
-
2009
- 2009-03-10 MY MYPI2010004253A patent/MY173730A/en unknown
- 2009-03-10 BR BRPI0909439A patent/BRPI0909439A2/pt not_active Application Discontinuation
- 2009-03-10 PE PE2009000349A patent/PE20091620A1/es not_active Application Discontinuation
- 2009-03-10 JP JP2010536259A patent/JP5604304B2/ja not_active Expired - Fee Related
- 2009-03-10 KR KR1020107022551A patent/KR20100129761A/ko not_active Ceased
- 2009-03-10 WO PCT/JP2009/054983 patent/WO2009113703A2/en not_active Ceased
- 2009-03-10 CN CN201410370293.2A patent/CN104127368A/zh active Pending
- 2009-03-10 CL CL2009000557A patent/CL2009000557A1/es unknown
- 2009-03-10 CN CN200980116971.XA patent/CN102026627B/zh not_active Expired - Fee Related
- 2009-03-10 EA EA201071054A patent/EA021792B1/ru not_active IP Right Cessation
- 2009-03-10 AU AU2009224254A patent/AU2009224254A1/en not_active Abandoned
- 2009-03-10 GE GEAP2009011969 patent/GEP20135845B/en unknown
- 2009-03-10 UY UY0001031698A patent/UY31698A/es not_active Application Discontinuation
- 2009-03-10 EP EP09720410A patent/EP2254556A2/en not_active Withdrawn
- 2009-03-10 US US12/921,731 patent/US9241910B2/en active Active
- 2009-03-10 MX MX2010009824A patent/MX2010009824A/es not_active Application Discontinuation
- 2009-03-10 AR ARP090100842A patent/AR070863A1/es unknown
- 2009-03-10 CA CA2717947A patent/CA2717947C/en active Active
- 2009-03-10 TW TW098107630A patent/TWI441658B/zh not_active IP Right Cessation
- 2009-03-10 NZ NZ588407A patent/NZ588407A/en not_active IP Right Cessation
- 2009-03-10 PE PE2014000364A patent/PE20141034A1/es not_active Application Discontinuation
-
2010
- 2010-09-05 IL IL207989A patent/IL207989A0/en unknown
- 2010-09-10 DO DO2010000273A patent/DOP2010000273A/es unknown
- 2010-09-17 ZA ZA2010/06679A patent/ZA201006679B/en unknown
- 2010-09-29 MA MA33210A patent/MA32174B1/fr unknown
- 2010-09-30 CR CR11709A patent/CR11709A/es unknown
- 2010-10-11 CO CO10125889A patent/CO6321224A2/es not_active Application Discontinuation
- 2010-10-11 EC EC2010010538A patent/ECSP10010538A/es unknown
-
2014
- 2014-10-21 US US14/519,979 patent/US20150037423A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513204A5 (enExample) | ||
| US11147772B2 (en) | Timed, pulsatile release systems | |
| CN1886119B (zh) | 泮托拉唑多颗粒制剂 | |
| US9095513B2 (en) | Enteric coated granule and method for preparing the same | |
| CN101977593A (zh) | 包含弱碱性药物以及有机酸的给药系统 | |
| US20090004284A1 (en) | Controlled release tamsulosin hydrochloride formulation | |
| KR20160115995A (ko) | 지속 방출 특성을 가지며 에탄올의 영향에 대한 저항성을 갖는 약제학적 또는 건강기능성 조성물 | |
| JP2000053563A (ja) | 苦味がマスクされた速放性細粒剤 | |
| US20090136550A1 (en) | Modified release formulations of diltiazem | |
| US20100080846A1 (en) | Dipyridamole and acetylsalicylic acid formulations and process for preparing same | |
| EP3184101A1 (en) | Levodopa and carbidopa modified release composition | |
| JP2015151337A (ja) | 医薬用組成物の製造方法、医薬用組成物、及び口腔内崩壊錠 | |
| US20100239681A1 (en) | Controlled Release Particulates Containing Water-Insoluble Drug | |
| US20100303920A1 (en) | Aqueous Film Coating Composition / 841 | |
| AU2013273835B2 (en) | Timed, pulsatile release systems | |
| KR20110029250A (ko) | 양성자 펌프 억제제 함유 약학 조성물 | |
| HK1108116B (en) | Timed, pulsatile release systems | |
| HK1189799A (en) | Timed, pulsatile release systems |